Ovid Therapeutics (OVID) Price & Analysis

Compare

1,443 Followers

OVID Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.24 - $1.47

Previous CloseN/A

Volume22.63K

Average Volume (3M)2.38M

Market Cap

$35.55M

Enterprise Value-$6.41M

Total Cash (Recent Filing)$43.00M

Total Debt (Recent Filing)$14.43M

Price to Earnings (P/E)―

Beta1.95

Next Earnings

Aug 18, 2025

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding71,109,510

10 Day Avg. Volume1,501,536

30 Day Avg. Volume2,376,597

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.18

Enterprise Value/Revenue-11.69

Enterprise Value/Gross Profit-16.02

Enterprise Value/Ebitda0.11

Forecast

1Y Price Target

$2.83

Price Target Upside466.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Drug EfficacyOV329 has key advantages over Vigabatrin, including data suggesting that OV329 works at doses 1000x lower than Vigabatrin.

Financial StabilityThe financial position of Ovid Therapeutics is stable, with sufficient cash to fund operations into the second half of 2026.

Safety ProfileOV329 shows no evidence of ocular accumulation in the current Phase 1 study, which is promising regarding its safety profile.

Bears Say

Drug RightsTakeda discontinued development of Soticlestat in Dravet syndrome, and Ovid does not regain rights to the drug, impacting revenue projections.

Price Target ReductionThe 12-month price target has been reduced to $1.50 from $2.

Ovid Therapeutics News

Ovid Therapeutics management to meet with B. Riley

Meeting to be held in New York on July 22 hosted by B. Riley. Published first on TheFly...

22d ago

OVID

Ovid Therapeutics Approves Key Proposals at Annual Meeting

Ovid Therapeutics ( ($OVID) ) has provided an update. On July 9, 2025, Ovid Therapeutics held its annual...

26d ago

OVID

Ovid Therapeutics Sells Ganaxolone Royalties to Immedica

Ovid Therapeutics ( ($OVID) ) has provided an announcement. On June 23, 2025, Ovid Therapeutics entered into an...

1M ago

OVID

Ovid enters agreement with Immedica for sale of future ganaxolone royalties

Ovid Therapeutics (OVID) announced that it has entered into a definitive agreement with Immedica Pharma AB for the...

1M ago

OVID

Ovid Therapeutics: Promising Buy Opportunity with OV329 Advancements in Drug-Resistant Epilepsy

William Blair analyst Myles Minter has maintained their bullish stance on OVID stock, giving a Buy rating yesterday....

2M ago

OVID

Positive Outlook for Ovid Therapeutics: Buy Rating Supported by Promising OV329 Drug and Strategic Pipeline Development

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Ovid Therapeutics (OVID –...

2M ago

OVID

Ovid Therapeutics to host investor, media event on June 12

Ovid Therapeutics (OVID) will host an investor and media event on Thursday, June 12, 2025, on the topic...

2M ago

OVID

Ovid Therapeutics Reports Q1 2025 Financial Results

Ovid Therapeutics ( ($OVID) ) has released its Q1 earnings. Here is a breakdown of the information Ovid...

2M ago

OVID

Ovid Therapeutics price target lowered to $1.50 from $2 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Ovid Therapeutics (OVID) to $1.50 from $2 and keeps a...

2M ago

OVID

Ovid Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating

William Blair analyst Myles Minter has maintained their bullish stance on OVID stock, giving a Buy rating today....

3M ago

OVID

Ovid Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on OVID stock, giving a Buy rating today....

3M ago

OVID

Ovid Therapeutics reports Q1 EPS (14c), consensus (13c)

Reports Q1 revenue $130,000, consensus $25,000. “We’re off to a strong start across our pipeline and programs in...

3M ago

OVID

Ovid Therapeutics sees cash runway into 2H26

Cash, cash equivalents and marketable securities as of March 31, 2025 totaled $43.0 million. Published first on TheFly...

3M ago

OVID

Ovid Therapeutics Advances Pipeline Amid Financial Progress

Ovid Therapeutics ( ($OVID) ) has released its Q4 earnings. Here is a breakdown of the information Ovid...

4M ago

OVID

OVID FAQ

What was Ovid Therapeutics Inc’s price range in the past 12 months?

Ovid Therapeutics Inc lowest stock price was $0.24 and its highest was $1.47 in the past 12 months.

What is Ovid Therapeutics Inc’s market cap?

Ovid Therapeutics Inc’s market cap is $35.55M.

When is Ovid Therapeutics Inc’s upcoming earnings report date?

Ovid Therapeutics Inc’s upcoming earnings report date is Aug 18, 2025 which is in 12 days.

How were Ovid Therapeutics Inc’s earnings last quarter?

Ovid Therapeutics Inc released its earnings results on May 13, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.002.

Is Ovid Therapeutics Inc overvalued?

According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ovid Therapeutics Inc pay dividends?

Ovid Therapeutics Inc does not currently pay dividends.

What is Ovid Therapeutics Inc’s EPS estimate?

Ovid Therapeutics Inc’s EPS estimate is -0.16.

How many shares outstanding does Ovid Therapeutics Inc have?

Ovid Therapeutics Inc has 71,109,510 shares outstanding.

What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?

Ovid Therapeutics Inc reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -3.333%.

Which hedge fund is a major shareholder of Ovid Therapeutics Inc?

Currently, no hedge funds are holding shares in OVID

Ovid Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-36.31%

Trailing 12-Months

Asset Growth

-37.96%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ovid Therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Ovid Therapeutics (OVID) Earnings & Revenues

OVID Earnings Data >

OVID Stock 12 Month Forecast

Average Price Target

$2.83

▲(466.00%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.6030769230769231,0.8861538461538463,1.1692307692307693,1.4523076923076925,1.7353846153846157,2.0184615384615388,2.3015384615384615,2.5846153846153848,2.867692307692308,3.150769230769231,3.433846153846154,3.716923076923077,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.5130769230769231,0.7061538461538461,0.8992307692307693,1.0923076923076924,1.2853846153846156,1.4784615384615385,1.6715384615384616,1.8646153846153848,2.057692307692308,2.250769230769231,2.443846153846154,2.6369230769230767,{"y":2.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.4107692307692308,0.5015384615384615,0.5923076923076923,0.6830769230769231,0.7738461538461539,0.8646153846153846,0.9553846153846155,1.0461538461538462,1.136923076923077,1.2276923076923076,1.3184615384615386,1.4092307692307693,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.06,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >